Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Expected Total Market Size Of The Glioblastoma Multiforme Industry By The Forecast Year 2029?
The glioblastoma multiforme market has shown significant growth in recent years. Its value is projected to rise from $1.59 billion in 2024 to $1.7 billion in 2025, at a compound annual growth rate (CAGR) of 7.3%. This expansion during the historic period stems from factors such as the increasing incidence of glioblastoma multiforme, advancements in healthcare infrastructure, heightened awareness, improved access to advanced therapies, and an expanding aging population.
The glioblastoma multiforme market is projected to experience substantial growth in the upcoming years, with an expectation to reach $2.27 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 7.5%. This expansion during the forecast period is primarily driven by an increase in brain and other nervous system cancer cases, greater acceptance of surgical methods, enhanced public awareness, prompt disease diagnosis, and a surge in research and development activities. Key trends anticipated over this period include continued advancements in medical technology, improved imaging techniques, the rise of personalized treatment approaches, the application of artificial intelligence (AI) for diagnosis, and broader technological and scientific developments.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21191&type=smp
What Are The Top Growth Drivers Impacting The Glioblastoma Multiforme Market Outlook?
The glioblastoma multiforme market is expected to be driven forward by the increasing number of brain disorder cases. A brain disorder is defined as a condition that impacts the brain’s structure or function, leading to cognitive, emotional, or physical impairments. The rise in these cases is attributed to factors such as aging populations, extended life expectancy, lifestyle elements, and improved diagnostic abilities. A deeper understanding of brain disorders significantly advances research into glioblastoma multiforme (GBM), which in turn fosters better early detection methods, innovative treatments, and enhanced patient outcomes. By investigating various neurological conditions, scientists are able to uncover genetic and molecular connections that play a role in GBM development. For instance, in February 2025, Dementia Australia, an Australia-based non-profit organization, reported that approximately 433,300 Australians are currently living with dementia, a number predicted to climb to 812,500 by 2054. Additionally, younger-onset dementia impacts around 29,000 people in 2025, with projections indicating an increase to 41,000 by 2054. Therefore, the growing incidence of brain disorder cases will stimulate the expansion of the glioblastoma multiforme market.
Which Key Segments Fueling The Glioblastoma Multiforme Market?
The glioblastoma multiformemarket covered in this report is segmented –
1) By Drug Class: Chemotherapy Agents; Temozolomide; Carmustine; Lomustine; Other Drug Classes
2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI); Computed Tomography Scan (CT Scan); Biopsy; Other Diagnostic Tools
3) By Treatment Type: Surgery; Radiation Therapy; Chemotherapy; Immunotherapy; Tumor Treating Field Therapy; Other Treatment Types
4) By End-User: Hospitals; Cancer Research Institutes; Ambulatory Surgical Centers; Other End-Users
Subsegments:
1) By Chemotherapy Agents: Alkylating Agents; Platinum-Based Agents; Antimetabolites
2) By Temozolomide: Branded (Temodar); Generic Temozolomide
3) By Carmustine: Injectable Carmustine; Carmustine Wafers (Gliadel)
4) By Lomustine: Branded (Gleostine); Generic Lomustine
5) By Other Drug Classes: Targeted Therapy; Immunotherapy; Tumor-Treating Fields (TTF) Therapy
Which Ongoing Trends Are Expected To Shape The Glioblastoma Multiforme Market Outlook?
Key companies active in the glioblastoma multiforme market are dedicating efforts to creating sophisticated treatments, such as CAR T-cell therapies, to meet the urgent medical demands presented by this aggressive cancer. CAR T-cell therapies constitute an immunotherapy method where a patient’s T-cells are genetically modified to more effectively target and eradicate cancer cells. For example, in June 2023, Chimeric Therapeutics Limited, an Australian biotech firm, commenced a Phase IB clinical trial for its CHM 1101 (CLXT CAR T) therapy, aimed at recurrent or progressive glioblastoma multiforme (GBM). This trial, being conducted across several centers, intends to assess the therapy’s safety and efficacy, while also establishing the suitable Phase 2 dose. Preliminary Phase 1a results demonstrated disease stability, and this trial will expand upon these findings to support continued progress. The company plans to leverage the collected data to formulate a registration trial and solicit regulatory guidance.
Which Major Firms Are Strengthening Their Position In The Glioblastoma Multiforme Industry?
Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report
What Are The Key Regional Factors Influencing The Glioblastoma Multiforme Market Growth?
North America was the largest region in the glioblastoma multiforme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Glioblastoma Multiforme Market Report:
https://www.thebusinessresearchcompany.com/customise?id=21191&type=smp
Browse Through More Reports Similar to the Global Glioblastoma Multiforme Market 2025, By The Business Research Company
Glioblastoma Multiforme Gbm Treatment Global Market Report 2025
Spinal Surgery Devices And Equipment Global Market Report 2025
Cerebrospinal Fluid Management Csf Devices And Equipment Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model